Diagnostic orphaning: The dermatologist and the uninsured patients: What happens after the biopsy

Uninsured patients may receive an accurate dermatologic diagnosis and an appropriate recommendation, yet remain unable to obtain treatment because diagnostic and therapeutic services are often delivered by separate entities. We term this "diagnostic orphaning": the patient has a diagnosis, a clinician, and perhaps a referral, but no feasible route to care. This contribution proposes an adequate pathway as an ethical standard for determining when efforts to address financial barriers constitute an adequate treatment plan. An adequate pathway preserves clinical integrity, is reasonably feasible, and includes accountable follow-through. Clinical integrity requires disclosure of the preferred treatment, reasonable alternatives, and consequences of delay or nontreatment. Less costly care is ethical only when medically acceptable and its limitations are transparent. Practical feasibility requires assessing whether a receiving site will accept the patient, whether care can be delivered within an appropriate interval, and whether the full episode of care is affordable. Accountable follow-through requires verifying subsequent handoffs and having a contingency plan if a referral fails. These obligations should reflect disease urgency, the likely harm from delay, and the potential benefit of further coordination; they do not require clinicians to guarantee access or personally finance the treatment plan. Practices and health systems should support referral coordination and comprehensive financial assistance, whereas professional organizations and the government should address barriers beyond individual clinicians' control. Pathway adequacy distributes responsibility according to each stakeholder's capacity to help patients obtain care.